ACADIA Pharmaceuticals Inc. (ACAD) announced after the bell Wednesday that it presented results from its Phase III -020 Study with pimavanserin in patients with Parkinson's disease psychosis at the 65th American Academy of Neurology Annual Meeting.
Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant antipsychotic efficacy on the 9-item SAPS-PD scale. Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson's Disease Rating Scale.
ACADIA Pharmaceuticals gapped up Thursday and rose sharply until mid-morning. The stock closed up by 1.59 at $8.24 on strong volume and surged to a new high for the year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org